<DOC>
	<DOCNO>NCT00940771</DOCNO>
	<brief_summary>The hypothesis study treatment regimen contain Atazanavir combination Ritonavir work well regimens contain protease inhibitor ( PI , one 5 class HIV Medications ) and/or Non-nucleoside Reverse Transcriptase Inhibitor ( NNRTI , another class HIV medication ) control HIV disease child HIV+ high cholesterol high triglyceride . . In study , child high cholesterol high triglyceride result HIV medicine , PI NNRTI medication regimen change Atazanavir , PI combination low dose Ritonavir ( another PI ) . Atazanavir show adult result low cholesterol triglycerides PI 's NNRTI 's . The dose atazanavir ritonavir accord Package Insert drug FDA approve child . They continue take medication pre-study regimen . Children take study drug 24 week , able continue study drug study use commercially available drug . Lab test physical exam undertaken 4 week , 12 week 24 week start study drug determine effective new drug monitor possible side effect .</brief_summary>
	<brief_title>Equivalence Boosted Atazanavir Based Regimens Currently Effective HAART Regimens</brief_title>
	<detailed_description>The objective study see Atazanavir Ritonavir together effective child 's previous regimen keep level virus blood stream low level ca n't find combination effective previous regimen keep infection fight cell blood level . - To see cholesterol triglyceride level drop child switch Atazanavir Ritonavir medication regimen . - To see Atazanavir Ritonavir result increase patient satisfaction patient report adherence decrease symptom related medication side effect . Inclusion Criteria : - On medication regimen least 3 month - Weight equal great 25kg - Able swallow pill willing learn - Have parent guardian willing able sign inform consent - Not take medication interacts Atazanavir - Not currently take sustiva</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIV positive child elevate lipid level stable HAART least 3 month ( define regimen viral load &lt; 1000 6 month prior baseline visit ) . Weight equal great 25kg Able swallow pill willing learn Patients underlie hepatitis B C viral infection Previously demonstrate clinically significant hypersensitivity ( eg , StevensJohnson syndrome , erythema multiforme , toxic skin eruption ) component Reyataz® ( atazanavir ) . Taking medication highly dependent CYP3A UGT1A1 clearance Ergot medicine : dihydroergotamine , ergonovine , ergotamine , methylergonovine Cafergot® , Migranal® , D.H.E . 45® , ergotrate maleate , Methergine® , others ( use migraine headache ) . Orap® ( pimozide , use Tourette 's disorder ) . Propulsid® ( cisapride , use certain stomach problem ) . Triazolam , also know Halcion® ( use insomnia ) . Midazolam , also know Versed® ( use sedation ) , take mouth . Camptosar® ( irinotecan , used cancer ) . Crixivan® ( indinavir , use HIV infection ) . Cholesterollowering medicine Mevacor® ( lovastatin ) Zocor® ( simvastatin ) . Rifampin ( also know Rimactane® , Rifadin® , Rifater® , Rifamate® ) . St. John 's wort ( Hypericum perforatum ) , herbal product sell dietary supplement , Viramune® ( nevirapine , use HIV infection ) . Vfend® ( voriconazole ) . Patients grade 3 high elevation transaminase ( &gt; 10 X ULN ) Women Childbearing Potential unwilling unable use acceptable method avoid pregnancy entire study period . Women pregnant breastfeeding . Women positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lipids</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Pediatric</keyword>
	<keyword>treatment experience</keyword>
</DOC>